Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-08-23
2010-02-02
Cook, Lisa V (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007920, C436S501000, C436S514000, C436S518000, C436S528000, C422S050000, C422S067000, C422S067000, C424S009100, C424S184100
Reexamination Certificate
active
07655424
ABSTRACT:
A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.
REFERENCES:
patent: 4906439 (1990-03-01), Grenner
patent: 5051237 (1991-09-01), Grenner et al.
patent: 5147609 (1992-09-01), Grenner
patent: 5207987 (1993-05-01), Kureshy et al.
patent: 5290678 (1994-03-01), Jackowski
patent: 5518688 (1996-05-01), Gianino
patent: 5604105 (1997-02-01), Jackowski
patent: 5677277 (1997-10-01), Yatsu et al.
patent: 5710008 (1998-01-01), Jackowski
patent: 5744358 (1998-04-01), Jackowski
patent: 5747274 (1998-05-01), Jackowski
patent: 6235489 (2001-05-01), Jackowski
patent: 6602855 (2003-08-01), Jackowski et al.
patent: 6617308 (2003-09-01), Jackowski et al.
patent: 6627606 (2003-09-01), Jackowski et al.
patent: 6780606 (2004-08-01), Jackowski
patent: 7049397 (2006-05-01), Jackowski et al.
patent: 7294688 (2007-11-01), Jackowski et al.
patent: 2002/0160434 (2002-10-01), Jackowski et al.
patent: 2003/0119064 (2003-06-01), Valkirs et al.
patent: 2003/0199000 (2003-10-01), Valkirs et al.
patent: 2006/0211048 (2006-09-01), Jackowski et al.
patent: 2008/0096286 (2008-04-01), Jackowski et al.
patent: 2263063 (2004-08-01), None
patent: 1 802 337 (1998-03-01), None
patent: 96/32648 (1996-10-01), None
patent: WO 98/01471 (1998-01-01), None
patent: 00/52476 (2000-09-01), None
Gonzalez et al. (Brain Research Bulletin, vol. 26, No. 2, Feb. 1991, pp. 241-250—Abstract Only).
Kurumatani et al. (Stroke, 1998, vol. 29, pp. 1058-1062).
Abraha, H.D. et al., Serum S-100 Protein: relationship to clinical outcome in acute stroke, Ann. Clin. Biochem. (1997), 34, pp. 546-550.
Amiral et al., Design and Validation of a New Immunoassay for Soluble Forms of Thrombomodulin and Studies on Plasma, Hybridoma (1994), 13, 3, pp. 205-213.
Aso et al., Mechanisms of Elevation of Serum and Urinary Concentrations of Soluble Thrombomodulin In Diabetic Patients: Possible Application as a Marker for Vascular Endothelial Injury, Metabolism (1998), 47, 3, pp. 362-365.
Butterworth et al., Serum Neuron-Specific Enolase, Carnosinase and Their Ratio In Acute Stroke, Stroke (1996), 27, 11, pp. 2064-2068.
Büttner, T. et al., S-100 protein: Serum marker of focal brain damage after ischemic territorial MCA infarction, Stroke, (1997) 28, 10, pp. 1961-1965.
Cunningham et al., Serum neurone-specific enolase as an indicator of stroke volume, European Journal of Clinical Investigation, (1996), 26, pp. 298-303.
Cunningham et al., Serum neurone-specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction, European Journal of Clinical Investigation (1991), 21, pp. 497-500.
Fareed et al., Plasma Thrombomodulin Levels as a Predictor of Hemorrhage (and Thrombotic) Events in Patients on Long-Term Anticoagulant Treatment, Circulation (1997), 96, pp. 2765-2768.
Fassbender et al., Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke, J. Neurological Sci. (1997), 148, pp. 101-105.
Gao et al., Time-course of neurone-specific enolase and S-100 protein release during and after coronary artery bypass grafting, British Jour. of Anaesthesia (1999), 82,2, pp. 266-267.
Garcia-Alex et al., Neuron-specific Enolase and Myelin Basic Protein: Relationship of Cerebrospinal Fluid Concentration To The Neurologic Condition of Asphyxiated Full-Term Infants, Pediatrics, (1994) 93, pp. 234-240.
Hardemark, H.G. et al., S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage, J. Neurosurg. (1989) 71, pp. 727-731.
Huguet., “Significance of the biologicia assay of NSE (neuron specific enolase).”, Lyon Pharmaceuticals, 1993, vol. 44, No. 3, pp. 187-192.
Isgro, F. et al., A Predictive parameter in patients with brain related complications after cardiac surgery, European Journal of Cardio-thoracic Surgery (1997), 11, pp. 640-644.
Jansson et al.,,High Concentration of Thrombomodulin In Plasma Is Associated with Hemorrhage, Circulation (1997), 96, pp. 2938-2943.
Kaiser et al., Clinical biochemistry of neuron-specific enolase, Clinica Chimica Acta (1989), 183, pp. 13-32.
Kario et al., ‘Silent’ Cerebral Infarction Is Associated With Hypercoagulability, Endothelial Cell Damage and High Lp(a) Levels in Elderly Japanese, Vascular Biology(1996), 16, pp. 734-741.
Kim, J.S. et al., Serial Measurement of Interleukin-6, Transforming Growth Factor-β and S-100 Protein in Patients With Acute Stroke, Stroke (1996), 27, 9, pp. 1553-1557.
Lamers, K.J.B. et al., Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders, Acta Neurologica Scandinavica, vol. 92, 1995, pp. 247-251.
Mabe et al., Serum Neuron-Specific Enolase Levels After Subarachnoid Hemorrhage, Surg. Neurol. (1991), 36, pp. 170-174.
Missler et al., S-100 Protein and Neuron-specific Enolase Concentrations in Blood As Indicators of Infarction Volume and Prognosis In Acute Ischemic Stroke, Stroke (1997), 28, pp. 1956-1960.
Mokuno et al., Neuron-Specific Enolase and S-100 Protein Levels in Cerebrospinal Fluid of Patients With Various Neurological Diseases, J. Neurological. Sci. (1983), 60, pp. 443-451.
Persson et al., S-100 Protein and Neuron-Specific Enolase in Cerebrospinal Fluid and Serum: Markers of Cell Damage in Human Central Nervous System, Stroke (1987)18, pp. 911-918.
Raabe et al., Fatal secondary increase in serum S-100 protein after severe head injury, J. Neurosurgery (1999), 91, pp. 875-877.
Rosen et al., Increased Serum Levels of S-100 Protein Are Associated With Hypoxic Brain Damage After Cardiac Arrest, Stroke (1998), 29, pp. 473-477.
Rothoerl et al., S-100 Serum Levels After Major and Minor Head Injury, The Journal of Trauma: Injury, Infection and Critical Care, (1998), 45, 4, pp. 765-767.
Steinberg, R. et al., Experimental Brain Ischemia: Neuron-Specific Enolase Level in Cerebrospinal Fluid as as Index of Neuronal Damage, J.Neurochem. (1984), 43, 1, pp. 19-24.
Stevens et al., Neurone-specific enolase and N-acetyl-aspartate as potential peripheral markers of ischaemic stroke, European Journal of Clinical Investigation (1999), 29, pp. 6-11.
Strand et al., “Brain and plasma proteins in spinal fluid as markers for brain damage and severity of stroke.”, Stroke, (Dallas), 1984, vol. 15, No. 1, pp. 138-144.
Sulter, G. et al., “Increased serum neuron specific enolase concentrations in patients with hyperglycemic cortical ischemic stroke.”, Neuroscience Letters, 1998, vol. 253, No. 1, pp. 71-73.
Teasdale et al., Assessment of Coma and Impaired Consciousness, Lancet (1974) 2, pp. 81-84.
van Dongen et al., Normal serum concentrations of S-100 protein and changes in cerebrospinal fluid concentrations of S-100 protein during and after thoracoabdominal aortic aneuryism surgery: Is S-100 protein a biochemical marker of clinical value in detecting spinal chord ischemia?, J. Vascular Surgery (1998), 27, 2, pp. 344-346.
van Engelen et al., Age-Related Changes of Neuron-Specific Enolase, S-100 Protein and Myelin Basic Protein Concentrations in Cerebrospinal Fluid, Clin. Chem. (1992), 38, 6, pp. 813-816.
Wang et al., Rat Brain Capillary Thrombomodulin Structure and Function, Thrombosis Research (1998), 92, pp. 213-219.
Westaby et al., Serum S-100 Protein:A Potential Marker For Cerebral Events During Cardiopulmonary Bypass, Ann. Thoracic Surgery (1996), 61, pp. 88-92.
Wimmer-Greinecker et al., Neuropsychological Changes After Cardiopulmonary Bypass for Coronary Artery Bypass Grafting, Thoracic Cardiovascular Surg.(1998) 46, pp. 207-212.
Wunderlich et al., Early Neurobehaviora
Cook Lisa V
Cooley Godward Kronish LLP
Nanogen Inc.
LandOfFree
Method for diagnosing and distinguishing stroke and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosing and distinguishing stroke and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing and distinguishing stroke and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153778